THAR: tharimmune.com Company Total Sales

tharimmune.com - graphic logo of issuer THAR

Tharimmune, Inc. (THAR) is developing oncology drugs through strategic in-licensing of assets, which drives its growth dynamics. While portfolio diversification covers liver cancer and pruritus therapies, the lack of profitability leaves the business dependent on venture capital investments. The company's sales volatility clearly demonstrates this stage, and the value of 0.00 describes the current level of operating inflows, confirming the early-stage trial phase.

Tharimmune Corp (THAR) - Revenue and Sales Volume from 02/21/2024 to 02/18/2026

Comprehensive metric breakdowns and analytics for Tharimmune Corporation (THAR)

- market price and analyst price targets:
- market capitalization information:
Comprehensive company analysis:THAR tharimmune.com
Flagship merchandise of Tharimmune Corp

This indicator captures the aggregate daily cash flow from product sales, determining the real-time speed of operating income generation. By analyzing the sales dynamics of Tharimmune, Inc. (THAR), investors assess the stability of market share and the business's ability to generate liquidity without relying on borrowed funds. The metric is sensitive to consumer demand, where stagnating values signal a risk of capital freeze. For the biotech startup Tharimmune, Inc. (THAR), such volumes confirm the effectiveness of attracting talent into immuno-oncology.

Analysis of competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|Company Total Revenue Citius Oncology Inc|HURA: Revenue and Sales Volume|TARA: Company Total Sales|FATE (fatetherapeutics.com) - Revenue and Sales Volume|Company Sales Aadi Bioscience Inc (WHWK)|Revenue and Sales Volume TCRX|CSBR - Company Total Revenue|Revenue and Sales Volume XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Company Total Revenue|OSTX: Company Sales|Company Sales Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Revenue|ANL: Company Total Sales|VERU (Veru Corporation) - Revenue and Sales Volume|Company Total Revenue Tempest Therapeutics, Inc. TPST|Revenue and Sales Volume XLO|Renovaro - Company Sales Volume|Company Revenue Mural Bio MURA|KAPA: Company Sales Volume|OnKure Therapeutics - Revenue and Sales Volume|Company Gross Revenue w2.cytomed.sg GDTC|CRIS: Revenue and Sales Volume|Company Sales Apollomics Inc.|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue